VANCOUVER, British Columbia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that it has closed the first tranche of its previously announced upsized non-brokered private placement (the “Offering”) and has issued an aggregate of 3,000,000 units (the “Units”) at a price of $5.00 per Unit for aggregate gross proceeds of $15,000,000. As previously announced, Eric Sprott, one of Apollo Silver’s largest shar ...

Core Viewpoint - Apollo Silver Corp. has successfully closed the first tranche of its upsized non-brokered private placement, raising a total of $15,000,000 by issuing 3,000,000 units at a price of $5.00 per unit [1] Group 1: Offering Details - The first tranche included significant participation from Eric Sprott, who subscribed for 2,500,000 units, contributing $12,500,000 to the total proceeds [2] - Insiders of Apollo Silver also participated in the first tranche, acquiring a total of 471,000 units for gross proceeds of $2,355,000 [7] - The offering consists of units that include one common share and one common share purchase warrant, with each warrant allowing the purchase of a share at an exercise price of $7.00 for 24 months [9] Group 2: Shareholder Impact - Following the first tranche, Eric Sprott's ownership increased to 6,188,889 shares and 3,888,889 warrants, representing approximately 10.3% of the outstanding shares on a non-diluted basis and 15.8% on a partially-diluted basis [4] - Sprott's long-term investment strategy may involve acquiring additional securities or selling existing ones depending on market conditions [5] Group 3: Use of Proceeds - The net proceeds from the offering will be utilized to advance the Calico Silver Project in California, support community relations at the Cinco de Mayo Silver Project in Mexico, cover ongoing property maintenance costs, and for general corporate purposes [11][12] Group 4: Regulatory and Market Context - The first tranche remains subject to final approval from the TSX Venture Exchange [8] - The offering is classified as a "related party transaction" under Multilateral Instrument 61-101, with exemptions from certain requirements due to the market capitalization of the company [7]

Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - C3 Metals Inc. (TSXV: CCCM) (OTCQB: CUAUF) ("C3 Metals" or the "Company") is pleased to announce that it has entered into an agreement with Paradigm Capital Inc., as lead underwriter and on behalf of a syndicate of underwriters (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, 18,182,000 common shares of the Company ("Shares") at a price of $1.10 per Share (the "Is ...

Core Viewpoint - Rockland Resources Ltd. has successfully closed a tranche of a non-brokered private placement, raising a total of $1,088,000 through the issuance of 10,880,000 units at a price of $0.10 per unit [1][2] Group 1 - The private placement consists of units that include one common share and one transferable common share purchase warrant, with warrants exercisable at $0.15 per share for a period of 36 months [1] - A senior officer of the company has subscribed for 300,000 units as part of the private placement [2] - The remaining balance of the private placement is expected to close on January 27, 2026 [2] Group 2 - Proceeds from the private placement will be utilized to advance the Cole Gold Mines project in Red Lake, Ontario, as well as for general working capital [2] - Shares issued from the financing will be subject to a four-month hold period in accordance with Canadian securities laws [2] Group 3 - Rockland Resources Ltd. is focused on mineral exploration and the acquisition of mineral property assets for the benefit of its shareholders [3]

Core Viewpoint - Ekso Bionics Holdings, Inc. has entered into a private placement agreement to raise approximately $5.9 million through the sale of Series B Preferred Stock and warrants, aimed at enhancing its working capital and corporate purposes [1][3]. Group 1: Private Placement Details - The company will sell 5,852 shares of Series B Preferred Stock with a stated value of $1,000 per share, convertible into 711,922 shares of common stock at a conversion price of $8.22 per share [2]. - The warrants will allow the purchase of up to 355,960 shares of common stock at an exercise price of $8.22 per share, expiring five years from the initial exercise date [2]. - The closing of the private placement is expected around January 22, 2026, pending customary closing conditions [3]. Group 2: Financial Implications - The gross proceeds from the private placement are anticipated to be approximately $5.9 million before deducting fees and expenses [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]. - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7].

Core Viewpoint - VR Resources Limited successfully closed an upsized private placement, raising a total of $3,150,000 through the sale of 19,687,500 units at a price of $0.16 per unit, including an over-allotment option [1][3]. Group 1: Offering Details - The offering was led by Centurion One Capital Corp. as the lead agent and sole bookrunner [2]. - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of one common share at an exercise price of $0.20 for 36 months [3]. - The company completed a consolidation of its common shares on a 10:1 basis prior to the offering, affecting the issue and exercise prices [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to exploration planning at the New Boston tungsten-moly-copper-silver project, Bonita copper-gold porphyry project, and Amsel epithermal gold-silver project in Nevada, as well as for marketing and general working capital [5]. - Near-term exploration plans include submitting a drill permit for the New Boston property and executing a contract for a 3D-array DCIP geophysical survey at the Bonita project [7]. Group 3: Additional Agreements - The company has entered into an agreement with ARES Capital Markets Group for investor relations and corporate communications services at a rate of USD$90,000 per month for two months [7][8].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].

Core Viewpoint - San Lorenzo Gold Corp. has successfully completed the final closing of its private placement, raising a total of approximately $5.99 million for exploration and working capital purposes [1][2]. Group 1: Private Placement Details - The final closing involved the issuance of 5,567,193 units for gross proceeds of $3,451,659.66, bringing the total raised under the offering to $5,999,999.78 [1]. - Each unit consists of one common share and one half of a share purchase warrant, with full warrants allowing the purchase of additional common shares at $0.80 for two years [1]. - Cash commissions of $179,408.90 were paid, and 15,862 broker warrants were issued, each allowing the purchase of a common share at $0.80 for one year [1]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated to exploration efforts on the Salvadora property and for general working capital, including offering expenses [2]. Group 3: Advisory Agreement - San Lorenzo will enter into an amended advisory engagement agreement with Argonaut Corporate Finance Limited, granting 1,000,000 stock options at $0.80 per share for two years [3]. - These options replace previously planned advisory warrants as part of the compensation for Argonaut [3]. Group 4: Company Focus - San Lorenzo is advancing its flagship Salvadora property in Chile's mega-porphyry belt, currently conducting a phase 6 drilling program on two of five identified targets [4]. - Previous drilling phases have indicated the presence of significant gold and copper enriched systems within the Salvadora property [4].

Core Viewpoint - Syntheia Corp. has announced a non-brokered private placement of up to 17,500,000 units at a price of $0.12 per unit, aiming to raise gross proceeds of up to $2,100,000 for general working capital purposes [1][3]. Group 1: Offering Details - Each unit consists of one common share and one-half of a transferable common share purchase warrant, with each whole warrant exercisable into one common share at a price of $0.20 for 36 months from the closing date [2]. - The offering is scheduled to close on or about February 20, 2026, subject to necessary regulatory approvals [5]. - A cash commission of 8.0% on the gross proceeds and finder warrants equal to up to 8.0% of the number of units sold will be paid to eligible finders [6]. Group 2: Regulatory Compliance - The units will be offered to purchasers in all Canadian provinces except Quebec, under the Listed Issuer Financing Exemption, and will not be subject to a statutory hold period [3]. - The offering may also be available in the United States and other jurisdictions through private placements, adhering to applicable laws [3]. Group 3: Company Overview - Syntheia is a provider of conversational AI solutions focused on inbound telephone call management, developing proprietary algorithms for human-like conversations [7]. - The company is acquiring call centers to enhance customer satisfaction while addressing staffing challenges [7].